GenSight Biologics
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, GenSight Biologics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
GenSight Biologics: 6 sponsored US clinical trials, none currently recruiting.
GenSight Biologics sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 4 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Optic, Atrophy, Hereditary, Leber, with 1 trials.
Upper-quartile sponsor footprint
GenSight Biologics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
NCT03326336
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
NCT03293524
RESCUE and REVERSE Long-term Follow-up
NCT03406104
REALITY LHON Registry
NCT03295071
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation
NCT02652767
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)
NCT02652780
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 4 |
Therapeutic Areas
How the GenSight Biologics archive is shaped
6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).
Phase mix: 4 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Optic, Atrophy, Hereditary, Leber (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
GenSight Biologics: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
GenSight Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this GenSight Biologics page
6 registered trials is a research-attention snapshot, not an endorsement of GenSight Biologics or any single study.
- None of GenSight Biologics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Optic, Atrophy, Hereditary, Leber is the condition GenSight Biologics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Optic, Atrophy, Hereditary, Leber trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
GenSight Biologics pipeline card: 6 registered trials from official public datasets.Report a data error.